Niquette Hunt is an entrepreneur and successful executive with over 25 years of general management experience. Coming out of line management in both large corporations and start-ups (P&G, Warner Lambert, Revance Therapeutics, Amira Medical) Ms. Hunt has proven her ability to drive significant growth on a variety of businesses across multiple industries. She has successfully launched over twenty new products and every brand she has managed has increased in sales, market share and/or profits under her watch.
She founded Candesant Biomedical with the goal of alleviating the suffering of the 84 million people in the US who sweat too much. Candesant will provide a safe, efficacious and cost-effective solution for these individuals who represent a potential market of $2.1 Billion in the US alone.
Candesant’s first product is a non-invasive energy device that temporarily inactivates sweat glands and significantly reduces sweating for up to two months after a single treatment. The product will be marketed to dermatologists and other aesthetic physicians for use in a no-downtime procedure that takes less than 15 minutes in the office. Excessive sweating is a lifelong condition and as such provides a compelling recurring revenue opportunity for both the physician and the company. Ms. Hunt has guided the company through product development, pre-clinical studies and early clinical testing. Candesant closed an oversubscribed Series A financing led by blue chip investors including Polaris Partners.
Prior to founding Candesant Biomedical, Ms. Hunt served as the Senior Vice President of Commercial Development for Revance Therapeutics (NASDAQ: RVNC) which she joined in 2009. Ms. Hunt was instrumental in taking the company public in February 2014; raising over $110 million in the offering which was oversubscribed by more than 10X and completed a secondary offering six months later raising $140 million. In addition, Ms. Hunt guided all the commercial activities for the company’s product candidates: RT001, the first topically applied botulinum toxin (BoNTA) product and RT002, the first injectable BoNTA to show significantly longer duration of action compared to Botox®, the market leader.